Serotonin Syndrome

TL;DR

Serotonin syndrome is the highest-priority safety gate for Methylene Blue. FDA 2011/2016 safety communications warn that IV methylene blue combined with serotonergic drugs can cause potentially fatal serotonin syndrome. This is not a generic supplement caution: MB can inhibit monoamine oxidase, and the risk becomes clinically important when paired with SSRIs, SNRIs, MAOIs, clomipramine, linezolid, or other serotonergic agents.

For Vitals, this note is mainly a medication-safety triage node, not a wearable-detection model. HRV, resting heart rate, temperature, sleep, and readiness may be abnormal during acute toxicity, but no consumer wearable can rule it in, rule it out, or predict it.

Why it matters for Vitals

• MB is a high-interest mitochondrial/cognitive compound, but the interaction screen matters more than the optimization narrative.
• Many users considering cognitive or mood interventions may already be using serotonergic medication.
• Vitals should treat serotonergic co-medication as a hard stop for MB coaching unless a clinician is explicitly managing an emergency indication.
• Wearables can support escalation context only after symptoms appear; they are not a validated serotonin-toxicity detector.

Core safety rule

Methylene blue + serotonergic drugs = contraindicated outside clinician-managed emergency care.

High-risk medication classes from the MB canonical source include:

Class	Examples	Practical Vitals rule
SSRIs	fluoxetine, sertraline, paroxetine, citalopram, escitalopram, fluvoxamine	Block MB recommendation; clinician review required
SNRIs	venlafaxine, duloxetine, desvenlafaxine	Block MB recommendation; clinician review required
MAOIs	phenelzine, tranylcypromine, selegiline at higher exposure	Block MB recommendation; clinician review required
Tricyclics with serotonergic activity	clomipramine, amitriptyline	Block MB recommendation; clinician review required
Other serotonergic/MAOI-like drugs	linezolid; other serotonergic combinations	Block MB recommendation; clinician review required

Evidence boundary

• Confirmed for MB interaction risk: FDA safety communications and case reports support the methylene-blue + serotonergic-drug warning.
• Mechanism: MB can inhibit MAO-A/MAO-B in a dose-dependent way; MAO-A inhibition plus serotonergic medication can raise synaptic serotonin to toxic levels.
• Route caveat: the strongest warning is for IV MB, especially perioperative or acute medical use. The source still treats serotonergic co-use as a hard safety gate for non-emergency MB consideration because oral exposure is variable and not reliably predictable.

Symptom triage context

Symptoms classically include combinations of:

• mental-status change: agitation, confusion, delirium
• autonomic activation: fever, sweating, tachycardia, blood-pressure instability
• neuromuscular findings: tremor, clonus, hyperreflexia, rigidity
• GI symptoms: diarrhea, nausea

Vitals should not attempt to diagnose serotonin syndrome. If symptoms occur after MB plus serotonergic exposure, the safe product posture is urgent medical evaluation / emergency escalation.

Wearable / Vitals relevance

What may move during acute toxicity

• resting heart rate may rise
• HRV/readiness may deteriorate
• temperature may rise if fever develops
• sleep may fragment or collapse
• activity/restlessness may increase

What Vitals cannot do

• no validated Apple Watch, Oura, Garmin, CGM, HRV, temperature, or sleep-stage pattern diagnoses serotonin syndrome
• no wearable rule can safely clear MB use in a serotonergic-medication user
• no automated dose or washout recommendation should be deployed without clinical signoff

Practical screening logic

Before any non-emergency MB consideration, screen for:

1. SSRI/SNRI/TCA/MAOI/linezolid or other serotonergic medication exposure.
2. Recent fluoxetine exposure, because longer washout may be needed.
3. Polypharmacy, especially in older adults.
4. Other MB safety gates from the hub: G6PD deficiency, nitrates/PDE5 inhibitors, pregnancy, hepatic/renal impairment.

If serotonergic exposure is present, Vitals should route back to Methylene Blue safety framing and recommend clinician review rather than optimization guidance.

Related notes

• Methylene Blue — MB hub; contains FDA-approved indications, cognition evidence boundaries, PK uncertainty, and suitability-screen logic.
• HRV and Cardiovascular signatures — wearable signals that may be abnormal during acute illness but are not diagnostic.
• MAO-B Inhibition — aspirational mechanism link; not created in this batch because MB-specific MAO details stayed inside the hub.